A trial study conducted by researchers, encompassing 30 clinical centers worldwide, studied the effects of CBD in 225 Lennox-Gastaut Syndrome patients aged 2 to 55. Lennox-Gastaut Syndrome is a severe form of epilepsy characterized by multiple seizures that begin in early childhood.
The 225 patients with Lennox-Gastaut Syndrome selected for the study had two or more drop seizures per week. At the commencement of the study, the patients were split into three groups and given CBD dosages of 10 or 20 milligrams per kilogram of body weight or a placebo, twice a day for 14 weeks, in conjunction with their traditionally prescribed epilepsy medications. The patients then reported how many drop seizures they had during the treatment period.
The results of the study demonstrated that the patients receiving the 20mg/kg of body weight CBD dose had 41.9% less seizures and the patients receiving the 10mg/kg of body weight dose had 37.2% less seizures. Patient reported adverse symptoms included sleepiness, decreased appetite and diarrhea. Fourteen of the patients also had elevated liver aminotransferase concentrations (which are enzymes that catalyze a transamination reaction between an amino acid and an α-keto acid. They are important in the synthesis of amino acids, which form proteins).
The study concluded that both children and adults that received CBD, in conjunction with their traditional anti-epileptic medications, experienced a significant decrease in drop seizures during the trial with minimal adverse effects. For more information on this study, please see the link here.